Journal of Cancer Research and Clinical Oncology

, Volume 122, Issue 9, pp 559–565 | Cite as

Alterations of thep53, Rb andMDM2 genes in osteosarcoms

  • Carl W. Miller
  • Abdulkarim Aslo
  • Alvina Won
  • Michael Tan
  • Beatrice Lampkin
  • H. Phillip Koefflar
Original Paper Clinical Oncology


Molecular defects affecting tumor-suppressor genes are an important step in the genesis of sarcomas. For example, inheritance of a defectiveRb orp53 gene predisposes the carrier to develop osteosarcoma, among other malignancies. In this study, we have assessed the occurrence ofp53, Rb andMDM2 alterations in the same samples of osteosarcomas, along with representative samples of various other sarcomas. Point mutations of thep53 gene were found in 13 of 42 osteosarcomas and 1 of 8 leiomyosarcomas, and gross rearrangement of thep53 gene was demonstrated in 5 of 37 osteosarcomas. The retinoblastoma susceptibility gene (Rb) was either rearranged or deleted in 7 of 37 osteosarcomas, 1 of 7 soft-tissue sarcomas and 1 of 4 Ewing sarcomas. Remarkably, 5 of the osteosarcomas havingRb alterations also hadp53 mutations. Amplification and overexpression of theMDM2 oncogene may lead to increasedMDM2-p53 binding resulting in inactivation ofp53 function. A two- to threefold increase in the copy number ofMDM2 was detected in 7 of 37 samples, 5 of which were osteosarcomas. Amplification of theMDM2 gene occurred independently ofp53 mutation; one sample having threefold amplification ofMDM2 also had ap53 mutation. In summary, 34 alterations of thep53, Rb andMDM2 genes were found in 26 of 42 (62%) osteosarcomas.

Key words

p53 Rb MDMZ Osteosarcoma Sarcoma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abramson DH, Ronner HJ, Ellsworth RM (1979) Second tumors in nonirradiated bilateral retinoblastoma. Am J Ophthalmol 87: 624–637PubMedGoogle Scholar
  2. Andreassen A, Oyjord T, Hovig E, Holm R, Florenes VA, Nesland JM, Myklebost O, Hoie J, Bruland OS, Borresen AL, Fodstadt O (1993)p53 abnormalities in different subtypes of human sarcomas. Cancer Res 53:468–471PubMedGoogle Scholar
  3. Araki N, Uchida A, Kimura T, Yoshikawa H, Aoki Y, Ueda T, Takai S, Miki T, Ono K (1991) Involvement of the retinoblastoma gene in primary osteosarcomas and other bone and soft-tissue tumors. Clin Orthop 270:271–277PubMedGoogle Scholar
  4. Baker AR, McDonnell DP, Hughes M, Crisp TM, Mangelsdorf DJ, Haussler MR, Pike JW, Shine J, O'Malley BW (1988) Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci USA 85:3294–3298PubMedGoogle Scholar
  5. Brachman DG, Hallahan DE, Beckett MA, Yandell DW, Weichselbaum RR (1991)p53 gene mutations and abnormal retinoblastoma protein in radiation-induced human sarcomas. Cancer Res 51:6393–6396PubMedGoogle Scholar
  6. Buchman VL, Chumakov PM, Ninkina NN, Samarina OP, Georgiev GP (1988) A variation in the structure of the protein-coding region of the humanp53 gene. Gene 70:245–252PubMedGoogle Scholar
  7. Carbone D, Chiba I, Mitsudomi T (1991) Polymorphism at codon 213 within thep53 gene. Oncogene 6:91–92Google Scholar
  8. Cheng J, Haas M (1990) Frequent mutations in thep53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 10:5502–5509PubMedGoogle Scholar
  9. Fakharzadeh S, Trusko RS, George DL (1991) Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 10:1565–1569PubMedGoogle Scholar
  10. Feinberg AP, and Vogelstein B (1983) A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 132:6–13PubMedGoogle Scholar
  11. Forus A, Florenes VA, Maelandsmo GM, Meltzer PS, Fodstad O, Myklebost O (1993) Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: some amplica do not includeMDM2. Cell Growth Differ 4:1065–1070PubMedGoogle Scholar
  12. Fuchs N, Winkler K (1993) Osteosarcoma. Curr Opin Oncol 5:667–671PubMedGoogle Scholar
  13. Fung YK, Murphree AL, T'Ang A, Qian J, Hinrichs SH, Benedict WF (1987) Structural evidence for the authenticity of the human retinoblastoma gene. Science 236:1657–1661PubMedGoogle Scholar
  14. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryja TP (1986) A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323:643–646PubMedGoogle Scholar
  15. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in thep53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855–4878PubMedGoogle Scholar
  16. Harlow E, Williamson NM, Ralston R, Helfman DM, Adams TE (1985) Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53. Mol Cell Biol 5:1601–1610PubMedGoogle Scholar
  17. Hartwell LH, Kastan MB (1994) Cell cycle control and cancer. Science 266:1821–1828PubMedGoogle Scholar
  18. Iavarone A, Matthay K, Steinkirchner TM, Israel MA (1992) Germline and somaticp53 gene mutations in multifocal osteogenic sarcoma. Proc Natl Acad Sci USA 89:4207–4209PubMedGoogle Scholar
  19. Khatib ZA, Matsushime H, Valentine M, Shapiro DN, Sherr CJ, Look AT (1993) Coamplification of theCDK4 gene withMDM2 andGLI in human sarcomas. Cancer Res 53:5535–5541PubMedGoogle Scholar
  20. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH (1993)MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 53:16–18PubMedGoogle Scholar
  21. Laimins LA (1993) The biology of human papillomaviruses: from warts to cancer. Infect Agents Dis 2:74–86PubMedGoogle Scholar
  22. Lane DP, Crawford LV (1979) T antigen is bound to a host protein in SV40-transformed cells. Nature 278:261–263PubMedGoogle Scholar
  23. Lee WH, Bookstein R, Lee EY (1988) Studies on the human retinoblastoma susceptibility gene. J Cell Biochem 38:213–227PubMedGoogle Scholar
  24. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923–935PubMedGoogle Scholar
  25. Lubbert M, Mirro J Jr, Miller CW, Kahan J, Isaac G, Kitchingman G, Mertelsmann R, Herrmann F, McCormick F, Koeffler HP (1990) N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis. Blood 75:1163–1169PubMedGoogle Scholar
  26. Ludlow JW (1993) Interactions between SV40 large-tumor antigen and the growth suppressor proteins pRB and p53. FASEB J 7:866–871PubMedGoogle Scholar
  27. McCormick F, Harlow E (1980) Association of a murine 53,000-dalton phosphoprotein with simian virus 40 large-T antigen in transformed cells. J Virol 3:213–224Google Scholar
  28. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH (1990) Germ linep53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233–1238PubMedGoogle Scholar
  29. Masuda H, Miller C, Koeffler HP, Battifora H, Cline MJ (1987) Rearrangement of thep53 gene in human osteogenic sarcomas. Proc Natl Acad Sci USA 84:7716–7719PubMedGoogle Scholar
  30. Merlo GR, Cropp CS, Callahan R, Takahashi T (1991) Detection of loss of heterozygosity in tumor DNA samples by PCR. Biotechniques 11:166–170PubMedGoogle Scholar
  31. Miller CW, Aslo A, Tsay C, Slamon D, Ishizaki K, Toguchida J, Yamamuro T, Lampkin B, Koeffler HP (1990) Frequency and structure ofp53 rearrangements in human osteosarcoma. Cancer Res 50:7950–7954PubMedGoogle Scholar
  32. Momand J, Zambetti GP, Olson DC, George D, Levine AJ (1992) TheMDM-2 oncogene product forms a complex with thep53 protein and inhibits p53-mediated transactivation. Cell 69:1237–1245PubMedGoogle Scholar
  33. Moran E (1993) Interaction of adenoviral proteins with pRB and p53. FASEB J 7:880–885PubMedGoogle Scholar
  34. Mulligan LM, Matlashewski GJ, Scrable HJ, Cavenee WK (1990) Mechanisms ofp53 loss in human sarcomas. Proc Natl Acad Sci USA 87:5863–5867PubMedGoogle Scholar
  35. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B (1989) Mutations in thep53 gene occur in diverse human tumour types. Nature 342:705–708PubMedGoogle Scholar
  36. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B (1992) Amplification of a gene encoding ap53-associated protein in human sarcomas. Nature 358:80–83PubMedGoogle Scholar
  37. Oren M (1994) Relationship of p53 to the control of apoptotic cell death. Semin Cancer Biol 5:221–227PubMedGoogle Scholar
  38. Ozaki T, Ikeda S, Kawai A, Inoue H, Oda T (1993) Alterations of retinoblastoma susceptible gene accompanied by c-myc amplification in human bone and soft tissue tumors. Cell Mol Biol 39:235–242PubMedGoogle Scholar
  39. Pedeutour F, Suijkerbuijk RF, Forus A, Van Gaal J, Van de Klundert W, Coindre JM, Nicolo G, Collin F, Van Haelst U, Huffermann K, Turc-Carel C (1994) Complex composition and coamplification ofSAS andMDM2 in ring and giant rod marker chromosomes in well-differentiated liposarcoma. Genes Chromosomes Cancer 10:85–94PubMedGoogle Scholar
  40. Reifenberger G, Reifenberger J, Ichimura K, Meltzer PS, Collins VP (1994) Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 54:4299–4303PubMedGoogle Scholar
  41. Reissmann PT, Simon MA, Lee WH, Slamon DJ (1989) Studies of the retinoblastoma gene in human sarcomas. Oncogene 4:839–843PubMedGoogle Scholar
  42. Romano JW, Ehrhart JC, Duthu A, Kim CM, Appella E, May P (1989) Identification and characterization of ap53 gene mutation in a human osteosarcoma cell line. Oncogene 4:1483–1488PubMedGoogle Scholar
  43. Scheffer H, Kruize YC, Osinga J, Kuiken G, Oosterhuis JW, Leeuw JA, Schraffordt Koops H, Buys CH (1991) Complete association of loss of heterozygosity of chromosomes 13 and 17 in osteosarcoma. Cancer Genet Cytogenet 53:45–55PubMedGoogle Scholar
  44. Scholz RB, Kabisch H, Weber B, Roser K, Delling G, Winkler K (1992) Studies of the RB1 gene and the p53 gene in human osteosarcomas. Pediatr Hematol Oncol 9:125–137PubMedGoogle Scholar
  45. Shew JY, Ling N, Yang XM, Fodstad O, Lee WH (1989) Antibodies detecting abnormalities of the retinoblastoma susceptibility gene product (pp110RB) in osteosarcomas and synovial sarcomas. Oncogene Res 4:205–214PubMedGoogle Scholar
  46. Smith-Sorensen B, Gebhardt MC, Kloen P, McIntyre J, Aguilar F, Cerutti P, Borresen AL (1993) Screening for TP53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE). Hum Mutat 2:274–285PubMedGoogle Scholar
  47. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B (1994) Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 57:1–9PubMedGoogle Scholar
  48. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH (1990) Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348:747–749PubMedGoogle Scholar
  49. Stratton MR, Williams S, Fisher C, Ball A, Westbury G, Gusterson BA, Fletcher CD, Knight JC, Fung YK, Reeves BR, Cooper CS (1989) Structural alterations of the RB1 gene in human soft tissue tumours. Br J Cancer 60:202–205PubMedGoogle Scholar
  50. Stratton MR, Moss S, Warren W, Patterson H, Clark J, Fisher C, Fletcher CD, Ball A, Thomas M, Gusterson BA, Cooper CS (1990) Mutation of thep53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene. Oncogene 5:1297–1301PubMedGoogle Scholar
  51. Toguchida J, Ishizaki K, Sasaki MS, Ikenaga M, Sugimoto M, Kotoura Y, Yamamuro T (1988) Chromosomal reorganization for the expression of recessive mutation of retinoblastoma susceptibility gene in the development of osteosarcoma. Cancer Res 48:3939–3943PubMedGoogle Scholar
  52. Toguchida J, Ishizaki K, Nakamura Y, Sasaki MS, Ikenaga M, Kato M, Sugimoto M, Kotoura Y, Yamamuro T (1989) Assignment of common allele loss in osteosarcoma to the subregion 17p13 Cancer Res 49:6247–6251PubMedGoogle Scholar
  53. Toguchida J, Yamaguchi T, Ritchie B, Beauchamp RL, Dayton SH, Herrera GE, Yamamuro T, Kotoura Y, Sasaki MS, Little JB, Weichselbaum RR, Ishizaki K, Yandell DW (1992a) Mutation spectrum of thep53 gene in bone and soft tissue sarcomas. Cancer Res 52:6194–6199PubMedGoogle Scholar
  54. Toguchida J, Yamaguchi T, Dayton SH, Beauchamp RL, Herrera Geichselbaum RR, Yandell DW, Ishizaki K, Yamamuro T, Meyers PA, Little JB, Sasaki MS, et al (1992b) Prevalence and spectrum of germline mutations of thep53 gene among patients with sarcoma. N Engl J Med 326:1301–1308PubMedGoogle Scholar
  55. Wadayama B, Toguchida J, Shimizu T, Ishizaki K, Sasaki MS, Kotoura Y, Yamamuro T (1994) Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res 54: 3042–3048PubMedGoogle Scholar
  56. Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81:323–330PubMedGoogle Scholar
  57. Xu HJ, Hu SX, Hashimoto T, Takahashi R, Benedict WF (1989) The retinoblastoma susceptibility gene product: a characteristic pattern in normal cells and abnormal expression in malignant cells. Oncogene 4:807–812PubMedGoogle Scholar
  58. Yamaguchi T, Toguchida J, Yamamuro T, Kotoura Y, Takada N, Kawaguchi N, Kaneko Y, Nakamura Y, Sasaki MS, Ishizaki K (1992) Allelotype analysis in osteosarcomas: frequent allele loss on 3q, 13q, 17p, and 18q. Cancer Res 52:2419–2423PubMedGoogle Scholar
  59. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM (1992) Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937–948PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • Carl W. Miller
    • 2
  • Abdulkarim Aslo
    • 2
  • Alvina Won
    • 2
  • Michael Tan
    • 2
  • Beatrice Lampkin
    • 1
  • H. Phillip Koefflar
    • 2
  1. 1.Hematology and OncologyChildren's HospitalCincinnatiUSA
  2. 2.Division of Hematology/Oncology, Department of MedicineUCLA School of Medicine, Cedars-Sinai Medical CenterLos AngelesUSA

Personalised recommendations